Gilead Raday Biography and Net Worth

COO of Redhill Biopharma

Gilead Raday previously served as interim CEO of Sepal Pharma, and as a director at TK Signal and Morria Biopharmaceuticals. He is a graduate of the University of Cambridge (M.Sc. in Bioscience Enterprise) and the Hebrew University of Jerusalem (M.Sc. Neurobiology, BSc Mathematics and Biology).

What is Gilead Raday's net worth?: The estimated net worth of Gilead Raday is at least $97.65 million as of October 1st, 2026. Mr. Raday owns 176,910,000 shares of Redhill Biopharma stock worth more than $97,654,320 as of October 9th. This net worth approximation does not reflect any other assets that Mr. Raday may own. Learn More about Gilead Raday's net worth.
How do I contact Gilead Raday?: The corporate mailing address for Mr. Raday and other Redhill Biopharma executives is 21 Ha’arba’a Street, Tel Aviv, TA, 6473921. Redhill Biopharma can also be reached via phone at 972-3541-3131 and via email at [email protected]. Learn More on Gilead Raday's contact information.
Has Gilead Raday been buying or selling shares of Redhill Biopharma?: Gilead Raday has not been actively trading shares of Redhill Biopharma during the past quarter. Most recently, Gilead Raday sold 14,310,000 shares of the business's stock in a transaction on Thursday, October 1st. Following the sale, the chief operating officer now directly owns 176,910,000 shares in the company. Learn More on Gilead Raday's trading history.
Are insiders buying or selling shares of Redhill Biopharma?: During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 44,180,000 shares worth more than $0.00. The most recent insider tranaction occured on October, 1st when COO Gilead Raday sold 14,310,000 shares worth more than $0.00. Insiders at Redhill Biopharma own 6.8% of the company. Learn More about insider trades at Redhill Biopharma.
Information on this page was last updated on 10/1/2026.

Gilead Raday Insider Trading History at Redhill Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2026	Sell	14,310,000	$0.00	$0.00	176,910,000
7/10/2026	Sell	14,130,000	$0.00	$0.00	218,780,000
4/6/2026	Sell	15,740,000	$0.00	$0.00	261,060,000

Gilead Raday Buying and Selling Activity at Redhill Biopharma

Redhill Biopharma Company Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Today's Range

Now: $0.55

$0.54

$0.59

50 Day Range

MA: $0.60

$0.47

$0.90

2 Week Range

Now: $0.55

$0.44

$2.14

Volume

315,025 shs

Average Volume

897,317 shs

Market Capitalization

$3.34 million

P/E Ratio

N/A

Dividend Yield